Medical school, University of Birmingham, Birmingham, UK.
Translational Brain Science, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
Expert Rev Neurother. 2023 May;23(5):457-466. doi: 10.1080/14737175.2023.2206567. Epub 2023 Apr 28.
Idiopathic intracranial hypertension is characterized by raised intracranial pressure that triggers disabling headaches and can cause permanent visual loss. There is an increased incidence and prevalence of the condition linked to location-specific obesity rates. There are no licensed treatments for the condition. The majority of approaches to managing the disease prioritize resolution of papilledema. However, evidence is emerging that idiopathic intracranial hypertension is a systemic metabolic disease.
The aim of this review is to present the emerging pathophysiology evidence which is leading to novel targeted therapeutics. The diagnostic pathway is outlined. The current and potential management approaches for idiopathic intracranial hypertension are also discussed.
Idiopathic intracranial hypertension is a condition with metabolic dysregulation with systemic manifestations that are present over and above what can be expl.ained by obesity alone. While most of the current management of this condition focuses on the eyes, future management needs to address the disabling headaches and the systemic risks of preeclampsia, gestational diabetes, and major cardiovascular events.
特发性颅内高压的特征是颅内压升高,引发使人致残的头痛,并可能导致永久性视力丧失。该疾病的发病率和患病率与特定部位的肥胖率有关。目前还没有针对该疾病的许可治疗方法。管理这种疾病的大多数方法都侧重于解决视乳头水肿。然而,有证据表明特发性颅内高压是一种全身性代谢疾病。
本综述旨在介绍新出现的病理生理学证据,这些证据为新的靶向治疗提供了依据。概述了诊断途径。还讨论了特发性颅内高压的当前和潜在管理方法。
特发性颅内高压是一种代谢失调的疾病,其全身性表现超出了单纯肥胖所能解释的范围。虽然目前对这种疾病的大部分治疗都集中在眼睛上,但未来的治疗需要解决使人致残的头痛以及子痫前期、妊娠期糖尿病和重大心血管事件的系统性风险。